Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy

Morgan Hakki

Published online: 24 January 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Purpose of Review CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review recent developments in CMV antivirals and immune-based approaches to mitigating CMV infection.

Recent Findings Letermovir, an inhibitor of the CMV terminase complex, was approved in 2017 for primary CMV prophylaxis in adult seropositive allogeneic HCT recipients. Maribavir, an inhibitor of the CMV UL97 kinase, is currently in two phase 3 treatment studies. Adoptive immunotherapy using third-party T cells has proven safe and effective in preliminary studies. Vaccine development continues, with several promising candidates currently under study.

Summary No longer limited to DNA polymerase inhibitors, the prevention and treatment of CMV infections in the HCT recipient is a rapidly evolving field which should translate into improvements in CMV-related outcomes.

Keywords Cytomegalovirus · Hematopoietic cell transplant · Antiviral · Letermovir · Maribavir · Filociclovir

Introduction

In 1989, ganciclovir (GCV) became the first anticytomegalovirus (CMV) agent approved by the US Food and Drug Administration (FDA) for the treatment and prevention of CMV infection and disease, followed by foscarnet (FOS), cidofovir (CDV), and valganciclovir (Table 1). All of these agents target the CMV DNA polymerase encoded by the UL54 gene (pUL54) to ultimately inhibit viral DNA synthesis. While these agents have dramatically reduced the burden of CMV infection in the hematopoietic cell transplant (HCT) recipient [1], their use is often limited by toxicities such as myelosuppression and renal injury, and the development of resistance [2]. Therefore, agents with novel mechanisms of action and improved toxicity profiles are clearly needed. In 2017, letermovir became the first antiCMV agent with a mechanism of action other than inhibition of DNA polymerase activity to be approved by the FDA. This review will discuss recent developments in CMV antiviral agents and non-pharmacological interventions that may augment the ability to prevent and treat CMV infections in HCT recipients.

Letermovir

Mechanism of Action and Pharmacology

CMV genomic replication involves a rolling-circle mechanism that produces multiple genomic units linked in a head-to-tail manner (concatamers) [3]. The viral terminase complex cleaves concatameric viral DNA into full-length genomes and then packages a single genome into the viral nucleocapsid as part of new virion formation [3]. The core terminase complex is comprised of the proteins pUL51, pUL56, and pUL89; all three proteins are necessary for terminase function [4, 5]. Targeting the terminase complex represents an attractive therapeutic option since host cellular DNA replication does not require terminase functions and all three terminase proteins are individually essential for viral replication [6]. The first terminase inhibitors were the benzimidazole D-ribonucleosides such as BDCRB and TCRB [3]. Clinical development was halted after preclinical studies demonstrated...
unfavorable in vivo metabolism [7]. Other terminase inhibitors such as GW275175X [7] and tomeglovir (BAY 38-4766) [8] were not brought to clinical trials.

Letermovir is a 3,4-dihydroquinazoline derivative discovered to have activity against CMV by high-throughput screening of a compound library [9]. The 50% effective concentration (EC50) is in the 0.004-μM range, with a selectivity index > 15,000 [9]. The identification of letermovir resistance mutations L241P and R369S in UL56 along with the finding that letermovir impaired the formation of proper unit-length viral DNA genomes indicated that letermovir’s mechanism of action involved targeting the terminase complex [10]. Due to its mechanism of action, letermovir retains activity against CMV strains resistant to DNA polymerase inhibitors but, unlike DNA polymerase inhibitors, letermovir does not exhibit significant activity against HHV-6, HSV, or VZV [9, 11].

Letermovir can be administered intravenously or orally, is highly (~99%) protein bound, and is eliminated via biliary excretion [12]. Letermovir exerts mild-to-moderate inhibitory effects on cytochrome P450 (CYP) 3A and increases exposure to tacrolimus, sirolimus, and cyclosporine [13, 14]; these require monitoring and dose adjustment as needed when co-administered with letermovir. The dose of letermovir should be reduced by 50% (from 480 to 240 mg/day) when co-administered with cyclosporine [13]. Letermovir reduces voriconazole exposure but does not appear to affect posaconazole [15, 16]. Letermovir is contraindicated in persons receiving ergot alkaloids and in persons receiving certain statins along with cyclosporine [17]. Although letermovir is well tolerated in the setting of mild-to-moderate hepatic and renal impairment, it should be used with caution in severe hepatic impairment (ChildPugh Class C) and insufficient data exist to guide dose adjustments if the creatinine clearance is < 10 mL/min [18, 19].

**Clinical Experience**

Letermovir was safe and well tolerated in a phase 1 clinical trial [20]. A phase 2 study compared letermovir at doses of 60, 120, and 240 mg daily to placebo for the prevention of CMV reactivation in seropositive allogeneic HCT recipients [21]. The incidence of virologic failure, defined as either detectable CMV infection leading to discontinuation of the study drug and administration of preemptive therapy or the development of CMV end-organ disease, was lower in the 240-mg group (6%) than in the 120-mg group (19%), the 60-mg group (21%), and the placebo group (36%). No safety concerns were identified.

Letermovir prophylaxis was then evaluated in a phase 3, placebo-controlled study in CMV seropositive allogeneic HCT recipients [22••]. A subset of patients were categorized as CMV high-risk, including HLA-A, B, or DR mismatch related donor, HLA-A, B, C, and DRB1 mismatch unrelated...
donor, haploidentical donor, cord blood transplant, ex vivo T cell–depleted graft, or graft-versus-host disease (GVHD) of grade 2 or greater requiring ≥1 mg/kg/day prednisone (or equivalent). Letermovir prophylaxis at 480 mg/day (240 mg/day if co-administered with cyclosporine) was begun at a median of 9 days after HCT and continued through week 14 post-HCT, and during this time, weekly CMV PCR monitoring was performed. Preemptive therapy was initiated upon detection of viremia according to local practice, with protocol-suggested viral load thresholds of 150 copies/mL in high-risk patients and 300 copies/mL in non-high-risk patients. Patients with detectable viremia prior to randomization were excluded from the primary efficacy analysis. Letermovir prophylaxis met the primary endpoint of reduction in clinically significant CMV infection (requiring initiation of preemptive therapy or CMV disease) compared with placebo at 24 weeks (17.5% vs 41.8%). Since CMV disease was uncommon in both groups, this endpoint was largely defined by reduction in the need for initiation of preemptive therapy; as such, the benefit of letomerov prophyaxis will depend on the viral load threshold for initiating preemptive therapy. Importantly, letomerov prophylaxis was associated with a statistically significant reduction in all-cause mortality at 24 weeks, with this benefit being predominantly among high-risk patients. As CMV disease was rare and no single predominant cause of death was identified [23•], the reason(s) for the mortality benefit at week 24 remain unclear. The reduction in mortality appeared to correlate with the prevention of CMV viremia, raising the hypothesis that the beneficial impact of letomerov prophylaxis may be related to preventing indirect negative effects of CMV infection [24–26]. Adverse events including gastrointestinal effects (nausea, diarrhea), myelotoxicity, and nephrotoxicity were similar in the letomerov and placebo groups. Based on these results, letomerov was approved by the FDA for primary CMV prophylaxis in adult CMV seropositive allogeneic HCT recipients [17].

Resistance

The finding of letomerov resistance mutations in UL56 was important in elucidating its mechanism of action [10]. Subsequent in vitro studies identified multiple additional UL56 resistance mutations, typically located between codons 231 to 369 [27, 28]. Mutations in UL89 and UL51 conferring reduced susceptibility to letomerov have also been observed in vitro [29, 30]. Letermovir-resistant mutants do not display a significant growth defect compared to wild-type CMV, even with mutations which confer complete (>3000-fold) resistance, such as at codon C325 of UL56 [27]. Resistance appears to evolve more rapidly in vitro compared to foscarine, indicative of a relatively low barrier to resistance [27].

A single case of breakthrough infection with a letomerov-resistant strain containing the UL56 V236M mutation during low-dose (60 mg daily) letomerov occurred in the phase 2 prophylaxis study [31]. An analysis of resistance during the phase 3 prophylaxis study was performed, focusing on identifying resistance-associated mutations in UL56 primarily and UL89 secondarily [32•]. UL56 genotyping was successful in 50 out of 79 patients (63%) who received letomerov prophylaxis and experienced CMV infection through week 24. Four UL56 resistance mutations were identified in 3 patients (6% of 50 patients analyzed). These 3 patients represented 16.7% of patients (N=18) who experienced CMV infection while receiving letomerov prophylaxis and for whom UL56 genotyping was successfully performed. One of the 3 patients was viremic at the time letomerov prophylaxis was initiated (viral load < 151 copies/mL) and another patient missed 5 doses of letomerov. Of the four UL56 resistance mutations identified, two were previously documented resistance mutations (V236M and C235W), and two were novel mutations (E237G and R369T) at positions previously demonstrated to confer resistance in vitro [27, 28]. There were no UL89 substitutions documented that had previously been identified as conferring resistance in vitro [30]; UL51 was not analyzed. Outside of these studies, cases of breakthrough infection and disease with letomerov-resistant virus have been reported in adult and pediatric HCT recipients receiving letomerov primary or secondary prophylaxis [33–35].

Outstanding Questions

With a novel mechanism of action and proven ability to safely and effectively prevent CMV infection after HCT, letomerov represents a substantial addition to the CMV antiviral armamentarium that should demonstrably improve CMV-related outcomes in HCT recipients. However, important questions remain that will require additional study, including:

1. Determining the optimal duration of letomerov prophylaxis. In the phase 3 prophylaxis study, clinically significant CMV infection developed in ~ 10% of patients (~20% in those at high risk of CMV) between week 14, when letomerov was discontinued, and week 24 [22••]. This raises the question as to whether a longer duration of prophylaxis may be of benefit, as was found for valganciclovir after high-risk (CMV D+/R-) solid organ transplant (SOT) [36]. A phase 3 clinical trial will compare 100 vs 200 days of letomerov prophylaxis in CMV seropositive allogeneic HCT recipients, with the primary outcome measure being clinically significant CMV infection through week 28 post-HCT (NCT03930615).

2. Further defining the benefit of letomerov prophylaxis in high-risk HCT populations. High-risk patients comprised 31% of the total study population in the phase 3 prophylaxis study, with haploidentical transplant recipients comprising 14.3%, cord blood recipients 4%, and ex vivo T
cell–depleted recipients 2.5% [22••]. Additional study is needed, with some data already emerging [37, 38], to define the relative benefit of letermovir prophylaxis in specific high-risk HCT recipients who were relatively underrepresented in the study but for whom the benefit of letermovir prophylaxis appeared greatest.

3. Determining whether there is a role for letermovir in preemptive therapy or treatment of CMV disease. The use of letermovir monotherapy for these indications is not currently recommended due to the lack of supporting data. Notably, in the phase 3 prophylaxis study, 48 patients with detectable CMV viremia (viral load in all cases < 1000 copies/mL) prior to randomization received letermovir, thereby essentially receiving letermovir as preemptive therapy; of those, approximately 33% had clinically significant CMV infection by week 14 [22••, 39]. Additionally, concerns exist about the relatively low barrier to resistance in vitro, and emerging reports describe the development of resistance when used in the setting of active infection [40–43]. An ongoing clinical trial (NCT03728426) will evaluate the safety and efficacy of letermovir as salvage treatment of CMV infection or disease.

Given their distinct mechanisms of action, the combination of letermovir with DNA polymerase inhibitors represents an attractive possibility for the treatment of CMV due to the potential for additive or even synergistic antiviral activity. In one study, the combination of letermovir with the DNA polymerase inhibitors ganciclovir, foscarnet, and cidofovir demonstrated only an additive, not synergistic, effect in vitro [44]. However, another study found a small degree of synergy between letermovir and brincidofovir, an oral prodrug of cidofovir [45]. More work, both clinical and in vitro, is required to address the potential utility of letermovir-based combination therapy.

4. Determining the safety and efficacy of letermovir in pediatric HCT recipients. Studies of letermovir to date have been limited to adult patients. A phase 2b study of letermovir in pediatric HCT recipients is underway (NCT03940586) in order to provide much needed information pertaining to optimal dosing, safety, and efficacy in this population.

### Maribavir

#### Mechanism of Action and Pharmacology

Maribavir is an orally available, benzimidazole L-riboside ATP competitive inhibitor of the CMV UL97 kinase (pUL97) [46]. This mechanism of action was revealed through selection of a resistant virus containing a mutation in UL97 [46]. pUL97 is a broadly acting kinase that phosphorylates viral and host cellular proteins [47]. Unlike the CMV DNA polymerase pUL54 or components of the terminase complex, pUL97 is not absolutely essential for replication in tissue culture [6]. Instead, mutant viruses deleted of the entire UL97 gene, or in which pUL97 kinase activity has been abrogated, are viable but display severe growth defects [6, 48–51]. The critical function(s) of pUL97 that contributes to efficient CMV replication and is affected by maribavir to result in inhibition of viral replication remains poorly defined.

Maribavir inhibits viral egress from the nucleus to the cytoplasm through inhibition of pUL97-dependent phosphorylation of the nuclear lamina component lamin A/C [52], although the relative contribution of this to maribavir’s overall antiviral activity remains to be determined.

The antiviral activity of maribavir is greatly affected by cell culture conditions, with an EC<sub>50</sub> in human embryonic lung (HEL) fibroblast cells of ~0.14 μM compared with ~13 μM in human foreskin fibroblast (HFF) cells [53]. The reason for this difference is not entirely clear, but one possibility is that cell conditions modulate the activity of cellular kinases which can compensate for loss of pUL97 activity in the presence of maribavir [53]. Indeed, the addition of cellular kinase inhibitors reduces the maribavir EC<sub>50</sub> in HFFs to values comparable to HELs [53]. Since maribavir inhibits pUL97 activity and ganciclovir depends on pUL97-mediated phosphorylation for its activity, maribavir and ganciclovir are antagonistic [53]. Maribavir retains activity against most CMV strains resistant to DNA polymerase inhibitors [46, 54, 55] but, similar to letermovir, is not active against other herpesviruses [55].

Maribavir is available only as an oral preparation and is ~30–40% absorbed after oral administration [56]. Based on studies in animals, maribavir is eliminated mainly by biliary excretion [56, 57]. Maribavir clearance is not affected by renal impairment [58]. Maribavir is not a significant inhibitor of major CYP enzymes and does not affect voriconazole exposure [59]. However, maribavir increases tacrolimus exposure by ~50% [60], and therefore monitoring of tacrolimus and sirolimus when co-administered with maribavir is recommended [59, 60, 61•].

#### Clinical Experience

Phase 1 clinical trials of maribavir evaluating doses up to 1200 mg twice daily showed maribavir to be safe and well tolerated, with the most common side effects being taste disturbance and headache [56, 62]. Maribavir was then evaluated in a multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase 2 prophylaxis study in adult CMV seropositive allogeneic HCT recipients [63]. The doses of maribavir evaluated were 100 mg twice daily, 400 mg once daily, and 400 mg twice daily to start at engraftment (between
patients cleared viremia after 6 weeks of maribavir treatment. Viral loads at initiation of maribavir at a starting dose of 400 mg twice daily [68]. Five patients (5 SOT recipients, 1 HCT recipient) treated with salvage or refractory infection, but the high rate of recurrence while on therapy and the associated emergence of maribavir resistance represent cause for concern. A phase 3 study of maribavir in HCT and SOT recipients with resistant or refractory CMV infections is underway (NCT02931539).

In parallel, a phase 2, open label study comparing maribavir to valganciclovir for preemptive therapy (absence of symptomatic infection or end-organ disease) following HCT or SOT was performed [69]. Patients were eligible if they had a CMV DNA viral load of 1000 to 100,000 copies/mL in blood or plasma. Patients were assigned to receive oral maribavir 400 mg, 800 mg, or 1200 mg twice daily or valganciclovir at a 900 mg twice daily for up to 3 weeks followed by 900 mg once daily for up to 12 weeks. The primary efficacy endpoint was the response to treatment, defined as undetectable CMV DNA in plasma within 3 weeks or 6 weeks after the start of treatment. Overall, 62% and 79% of patients had an undetectable viral load within 3 weeks and 6 weeks of maribavir treatment, respectively, compared with 56% and 67% for valganciclovir. No dose-dependent effect of maribavir on clearance of viremia was observed. The percentage of patients with recurrence of CMV infection at any time during the trial period was similar between maribavir and valganciclovir (22% vs 18%). Similar to other studies, altered taste was the most common adverse effect of maribavir (~40%), followed by other gastrointestinal adverse effects (nausea, vomiting, diarrhea). Myelosuppression was more common in those receiving valganciclovir. A phase 3 trial of maribavir 400 mg twice daily versus valganciclovir for the treatment of first episodes of asymptomatic CMV infection in HCT recipients with a plasma viral load of ≥1365 International Units (IU)/mL and ≤91,000 IU/mL is now underway, with the primary outcome measure being clearance of viremia by 8 weeks of treatment (NCT02927067).

Resistance

The UL97 mutations V353A, L397R, T409M, and H411L/N/Y emerge in vitro during maribavir selection and confer
moderate-to-high level (9-fold to > 200-fold) resistance [46, 70, 71]. The first report of resistance during clinical use developed in a patient receiving maribavir as salvage therapy for CMV infection and was associated with UL97 T409M and H411Y mutations [72]. Resistance was not documented in either the phase 2 or 3 prophylaxis studies in HCT recipients [63, 64]. Genotypic analysis of maribavir-breakthrough infections from the phase 2 salvage study revealed de novo resistance mutations in 13 of 25 (52%) (T409M in 10, H411Y in 3) patients; development of resistance was equal across all maribavir doses [61].

In general, resistance mutations in UL97 that arise during ganciclovir or maribavir selective pressure do not confer cross-resistance to the other agent [54, 73]. Surprisingly, however, one patient in the phase 2 salvage therapy study was retrospectively found to have a novel UL97 mutation F342Y after prolonged ganciclovir exposure but prior to beginning maribavir [74]. This mutation was found to confer GCV resistance and, unique to UL97 mutations selected during GCV exposure, cross-resistance to maribavir (4.5-fold). The patient went on to develop a UL97 H411Y mutation and eventually failed maribavir therapy.

Mutations in another CMV gene, UL27, arise under maribavir selection in vitro and also during propagation of UL97-defective strains [75–77], suggesting that mutations in this gene represent a fundamental mechanism of compensating for lack of pUL97 kinase activity. However, mutations in UL27 confer low-grade (2–3-fold) resistance to maribavir [75–77] and have not been identified during clinical use.

Filociclovir (Cyclopropravir)

Mechanism of Action

Filociclovir (formerly “cyclopropavir”) is a second-generation methylenecyclopropane nucleoside analog of 2′-deoxyguanosine [78]. Filociclovir, similar to GCV, is a nonobligate chain terminator of DNA synthesis that requires initial phosphorylation by pUL97, followed by additional phosphorylation steps performed by cellular kinases to its active triphosphate form [79–82]. Filociclovir EC\textsubscript{50} values for CMV strains are approximately 0.2–0.3 μM, which are ~5-fold less than for GCV [78, 83–85]. The increased potency of filociclovir compared with GCV in vitro may reflect the findings that filociclovir is a better substrate for pUL97 than GCV [80, 86] and the CMV DNA polymerase incorporates filociclovir-triphosphate into DNA more efficiently than GCV-triphosphates [82]. Filociclovir displays little cytotoxicity at concentrations required to inhibit CMV replication in a variety of cell types [81] and demonstrated efficacy in a mouse model of CMV infection [87]. In addition to CMV, filociclovir is active against HHV-6 but not HSV1, HSV2, or VZV [81].

In single-dose studies, oral bioavailability in rats and dogs ranged from 22 to 46% and 70 to 91%, respectively [88]. In single-dose rat toxicity studies, filociclovir was well tolerated up to 300 mg/kg [88]. Preclinical studies and data from a single-dose (range 35–1350 mg) human study suggest that filociclovir is primarily eliminated via renal excretion [89]. An L-valine ester prodrug, valyclopropavir, with 95% bioavailability in mice was synthesized [90] but has not been further developed for clinical use.

Clinical Experience

A phase 1b ascending dose (100 mg, 350 mg, or 750 mg once daily for 7 days) trial was conducted in normal, healthy volunteers [89]. No serious adverse events were reported. Drug exposure plateaued around the 350 mg dose. The mean plasma concentrations exceeded the CMV in vitro 90% inhibitory concentration (IC\textsubscript{90}) for doses ≥ 100 mg per day.

Resistance

Filociclovir selection in vitro generates resistance mutations at canonical UL97 GCV resistance sites M460, H520, and C603 [2, 83, 85]. Filociclovir also selects for novel UL97 mutations at positions F342 and V356, both of which individually confer cross-resistance to GCV and maribavir [51, 91]. Resistance mutations in the UL54 DNA polymerase also emerge under filociclovir selective pressure in vitro, some of which result in cross-resistance to GCV and/or FOS [85]. Conversely, filociclovir has been assayed against a variety of genotypically defined resistant CMV strains. Mutation at UL97 codon L595, one of the residues commonly involved in GCV resistance [2], confers no filociclovir resistance [83, 91]. However, mutations at the other canonical GCV resistance sites including M460, H520, C592, A594, and C603 [2] result in 3–20-fold increases in filociclovir EC\textsubscript{50} values [83, 91]. Thus, cross-resistance between filociclovir and GCV and/or FOS may occur depending on the site of mutation.

Brincidofovir

Brincidofovir (CMX001) is an oral lipid conjugate formulation of cidofovir with potent CMV activity [92]. In a phase 3 study in CMV seropositive allogeneic HCT recipients, brincidofovir prophylaxis for 14 weeks post-HCT did not meet the primary endpoint of prevention of CMV infection at week 24 compared with placebo [93•]. Brincidofovir was associated with significant gastrointestinal toxicity including acute GVHD and diarrhea [93, 94]. As such, oral brincidofovir is not being further developed as an antiCMV agent.
Vaccine Development

In 1999, the Institute of Medicine, now the National Academy of Medicine, designated CMV as a highest priority for vaccine development [95]. This has proven a challenge, and there are no vaccines currently available for use. ASP0113 was a DNA vaccine encoding glycoprotein B (gB), which is capable of eliciting neutralizing antibodies, and the tegument protein pp65, which is a primary target of T cell responses [96, 97]. Unfortunately, ASP0113 failed to meet primary (overall mortality, CMV disease) or secondary (time to viremia and use of preemptive therapy) endpoints in a placebo-controlled, phase 3 study in HCT recipients [96]. ASP0113 also failed to meet the primary endpoint of reducing the risk of viremia through 1 year after transplant compared with placebo in a phase 2 study in CMV D+/R- renal transplant [98].

More recently, vaccine development has focused on incorporating the pentameric complex [96, 99]. The pentameric complex consists of gH/gL/pUL128/pUL130/pUL131, is required for CMV entry into several clinically relevant cell types, and elicits potent neutralizing antibody responses that block entry into those cells [96, 99]. A CMV vaccine candidate (V160) incorporating the pentameric complex was constructed from the live attenuated CMV AD169 strain that was further engineered to be replication-defective in the absence of a synthetic compound called Shield-1 [100]. Recently, this vaccine was found to be safe and elicited robust levels of neutralizing antibodies and T cell responses when administered to CMV-seronegative subjects in a phase 1 study [101, 102]. Several other candidate vaccines are currently being evaluated in phase 1 and 2 trials in adult and pediatric HCT recipients [96].

Adoptive Immunotherapy and Passive Immunization

Adoptive immunotherapy denotes the reconstitution of CMV-specific T cell responses via the isolation, in vitro propagation, and transfusion of donor T cells to the recipient [103–106]. Adoptive immunotherapy has been safely used in HCT recipients as an adjunct to antiviral therapy for preemptive therapy and for the treatment of refractory CMV infection, and prophylactically after HCT, all in relatively small series [105, 107–114].

However, the need to generate specific T cell lines for each individual patient imposes logistical limitations for broad or immediate, time-sensitive use [115]. Using partially HLA-matched, banked third-party cells addresses these limitations [115]. The safety and tolerability of this approach in the management of refractory CMV infection or disease has been demonstrated in several nonrandomized studies [115, 116, 117•]. The majority of patients in these studies exhibited clinical and/or virologic responses following T cell infusion along with continued antiviral therapy. Thus, the incremental benefit of the transfused T cells is unclear. Randomized studies are now needed to definitively assess the benefit and safety of adoptive immunotherapy for the prevention or treatment of CMV infection in the HCT recipient [118].

The utility of intravenous immune globulin (IVIG) or CMV-enriched IgG in the management of CMV disease is unclear due to the lack of prospective, randomized trials evaluating the benefit of adjunctive IVIG compared with antiviral therapy alone. While not useful in the setting of gastrointestinal disease [119], the addition of IVIG to antiviral therapy in the management of pneumonia resulted in improved survival rates compared with historical controls in small studies [120–122]. However, a more recent, large retrospective analysis failed to demonstrate such a benefit [123] and therefore, the role of IVIG in the management of CMV pneumonia remains poorly defined. IVIG is not effective as prophylaxis in seronegative or seropositive HCT recipients [124–132].

A monoclonal antibody preparation that targets both the CMV glycoprotein B (gB) and the pentameric complex is in development [133]. A previous CMV monoclonal antibody that targeted the CMV gH protein (MSL-109) failed to demonstrate benefit when used as prophylaxis in HCT recipients [134].

Conclusions and Future Directions

The CMV DNA polymerase inhibitors GCV, FOS, and CDV, while critical developments in reducing the morbidity and mortality associated with CMV infection in HCT recipients, are marked by issues of toxicity and resistance that often limit their use. The approval of letermovir—a nontoxic, orally available agent with a mechanism of action distinct from DNA polymerase inhibition—represents an important step in expanding the options for CMV prevention and towards the greater goal of improving outcomes after HCT. Additionally, the success of letermovir validates terminase inhibitors as a clinically relevant class of antiviral agents and may open the door to the development of other terminase inhibitors [135].

As agents with novel mechanisms of action such as letermovir and possibly maribavir are brought to clinical use, combination therapy for the treatment of CMV infection and disease becomes, for the first time, a possibility. In vitro studies generally support at least an additive effect, if not a synergistic one, of combining letermovir with DNA polymerase inhibitors or maribavir. Clinical studies are now needed to determine whether combination therapy for CMV is superior to monotherapy, as is true for the treatment of viral infections such as human immunodeficiency virus and hepatitis C virus [136, 137]. With no other agents besides maribavir and filociclovir currently in human studies, combination therapy
with existing agents and perhaps with indirectly acting anti-CMV agents approved for other indications \([138–153]\) that are unsuitable for use as monotherapy should be considered.

Advances in non-pharmacologic interventions will also be important in mitigating the impact of CMV infection. The safety of third-party T cells for use in adoptive immunotherapy demonstrated in initial studies moves this therapeutic intervention further towards becoming a realistic, viable option for more patients. The development of a safe and effective CMV vaccine remains a challenge but promising candidates are in development.

**Acknowledgments** The author wishes to thank Dr. Sunwen Chou and Dr. Lynne Strasfeld for their critical review of the manuscript.

**Compliance with Ethical Standards**

**Conflict of Interest** The author declares no conflict of interest.

**Human and Animal Rights and Informed Consent** This article does not involve studies with human participants or animals performed by the author.

**References**

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.
2. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.
3. Bogner E. Human cytomegalovirus terminase as a target for anti-viral chemotherapy. Rev Med Virol. 2002;12(2):115–27.
4. Neuber S, Wagner K, Goldner T, Lischka P, Steinbrueck L, Messerle M, et al. Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation. J Virol. 2017;91(12).
5. Borst EM, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packing and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013;87(3):1720–32.
6. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A. 2003;100(24):14223–8.
7. Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, et al. Mechanism of action of the ribopyranoside benzimidazolone GW275175X against human cytomegalovirus. Antimicrob Agents Chemother. 2004;48(5):1467–51.
8. Buerger J, Reetschlagger J, Bender W, Eckenberg P, Popp A, Weber O, et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol. 2001;75(19):9077–86.
9. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54(3):1290–7.
10. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–93.
11. Marschall M, Stamming T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012;56(2):1135–7.
12. Piret J, Boivin G. Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antivir Res. 2019;163:91–105.
13. Kropeit D, von Richter O, Stobernack HP, Rufsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(1):9–21.
14. McCrea JB, Macha S, Adevoyin A, Marshall W, Menzel K, Cho CR, et al. Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharmacol. 2019;59(10):1331–9.
15. Duong A, Sweet A, Jain R, Hill JA, Pergam SA, Boeckh M, et al. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2019.
16. Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897–904.
17. PREVYMIS: Package insert and label information [press release]. 2017.
18. Kropeit D, McCormick D, Erb-Zohar K, Moiseev VS, Kobalava ZD, Stobernack HP, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in patients with renal impairment. Br J Clin Pharmacol. 2017;83(12):2678–86.
19. Kropeit D, Scheuenplug J, Erb-Zohar K, Halabi A, Stobernack HP, Hulskotte EGJ, et al. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol. 2017;83(9):1944–53.
20. Erb-Zohar K, Kropeit D, Scheuenpflug J, Stobernack HP, Hulskotte E, van Schanke A, et al. Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial. Clin Transl Sci. 2017;10(6):487–95.
21. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–9.
22. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44 Phase 3 study of letermovir that led to FDA approval for use as prophylaxis in CMV seropositive allogeneic HCT recipients.
23. Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2019; Analysis of mortality benefit observed in HCT recipients receiving prophylaxis as part of the phase 3 study.
24. Nichols WG, Corel L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from

Editorial comments for Curr Hematol Malig Rep (2020) 15:90–102
seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–82.
25. Schmidt-Hieber M, Labopin M, Beelen D, Vinon L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3539–64.
26. Teira P, Battwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38.
27. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588–93.
28. Goldner T, Hempel C, Ruesbsamen-Schaeff H, Zimmermann H, Lischka P. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–3.
29. Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antivir Res. 2017;148:1–4.
30. Chou S. Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. Antimicrobial agents and chemotherapy. 2017;61(11).
31. Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213(1):23–30.
32. • Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M, et al. Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis. 2019; Analysis of letermovir resistance from the phase 3 prophylaxis study in HCT recipients.
33. Kilgore JT, Becken B, Varga MG, Parikh S, Prasad V, Lugo D, et al. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient. J Pediatric Infect Dis Soc. 2019.
34. Knoll BM, Seiter K, Phillips A, Soave R. Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transplant. 2019;54(6):911–2.
35. Popping S, Dalm V, Lukbe N, Cristanziano VD, Kaisser R, Boucher CAB, et al. Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency. Open Forum Infect Dis. 2019;6(9):ofz375.
36. Humar A, Lebranchu Y, Vincenzi F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days ganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228–37.
37. Sharma P, Gakhur N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2019.
38. Lin A, Maloy M, Su Y, Bhattacharjee PI, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;e13187.
39. Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2019.
40. Frietsch JJ, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U, et al. In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2019;11(1):e2019001.
41. Cherrier L, Nasar A, Goodlet KJ, Nailer MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018;18(12):3060–4.
42. Jung S, Michel M, Stamminger T, Michel D. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis. 2019;19(1):388.
43. Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrobial agents and chemotherapy. 2019;63(3).
44. Wildum S, Zimmermann H, Lischka P. In vitro dual drug combination studies of letermovir (AIC246, MK-8228) with approved anti human cytomegalovirus (HCMV) and HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015.
45. O'Brien MS, Markovich KC, Selleseh D, DeVita AV, Sethna P, Gentry BG. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antivir Res. 2018;158:255–63.
46. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46(8):2365–72.
47. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19(4):215–29.
48. Azzez M, Honigman A, Taraboulos A, Rouvinski A, Wolf DG. Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology. 2006;354(1):69–79.
49. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol. 1999;73(7):5663–70.
50. Weibel R, Hakki M, Prichard MN, Rawlinson WD, Marshall M, Chou S. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol. 2014;88(9):4776–85.
51. Chou S, Ercolani RJ, Maroucek G, Bowlin TL. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother. 2013;57(7):3375–9.
52. Hamirally S, Kamil JP, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Differential properties of cytomegalovirus pUL97 kinase isoforms following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2019.
53. Lin A, Maloy M, Su Y, Bhattacharjee PI, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;e13187.
54. Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2019.
55. Lin A, Maloy M, Su Y, Bhattacharjee PI, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;e13187.
56. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother. 2003;47(7):2186–92.
57. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47(4):1334–42.
57. Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002;46(8):2373–80.

58. Swan SK, Smith WB, Marbury TC, Schumacher M, Dougherty C, Mico BA, et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol. 2007;47(2):209–17.

59. Song IH, Ilic K, Murphy J, Lasseter K, Martin P. Effects of maribavir on P-glycoprotein and CYP2D6 in healthy volunteers. J Clin Pharmacol. 2019.

60. Pescevitz MD, Bloom R, Pirsch J, Johnson J, Gelone S, Villano S. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant. 2009;9(10):2324–30.

61. Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, et al. Maribavir for refractory or resistant cytomegalovirus infection in human immune-deficient or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255–64 This study demonstrated that maribavir may be a viable option for the treatment of resistant/refractory CMV infection in HCT and SOT recipients. Results from the phase 3 study will be most informative.

62. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46(9):2969–76.

63. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–10.

64. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus infections in hematopoietic-cell- or solid-organ transplant recipients: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92.

65. Winston DJ, Saliba F, Blumberg E, Abouljou M, Garcia-Diaz JB, Goss JA, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021–30.

66. Marty FM, Boechk M. Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed? Current opinion in virology. 2011;1(6):555–62.

67. Snyderman DR. Why did maribavir fail in stem-cell transplants? Lancet Infect Dis. 2011;11(4):255–7.

68. Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489–96.

69. Maertens J, Cordonnier C, Jaksch P, Poire X, Uknis M, Wu J, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381(12):1136–47 This study demonstrated the potential utility of maribavir as preemptive therapy in HCT and SOT recipients. A phase 3 study in HCT recipients is underway.

70. Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol. 2008;82(1):246–53.

71. Chou S, Van Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis. 2007;196(1):91–4.

72. Strasfeld L, Lee I, Villano S, Chou S. Virologic characterization of multi-drug-resistant cytomegalovirus infection in two transplant recipients treated with maribavir. J Infect Dis. 2010;202(1):104–8.

73. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18(4):233–46.

74. Chou S, Wu J, Song K, Bo T. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antivir Res. 2019;172:104616.

75. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother. 2009;53(1):81–5.

76. Chou S, Marousek GI, Senters AE, Davis MG, Biron KK. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol. 2004;78(13):7124–30.

77. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol. 2003;77(21):11499–506.

78. Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E, et al. Synthesis and antiviral activity of (Z)- and (E)-2-[bis(hydroxymethyl)methylene]propylenedi)methylpurines and -pyrimidines: second-generation methylene-cyclopropyl analogues of nucleosides. J Med Chem. 2004;47(3):566–75.

79. Gentry BG, Gentry SN, Jackson TL, Zemlicka J, Drach JC. Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase. Biochem Pharmacol. 2011;81(1):43–9.

80. Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob Agents Chemother. 2010;54(8):3093–8.

81. Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA, Zhou S, et al. In vitro activity and mechanism of action of methylene-cyclopropyl analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother. 2005;49(3):1039–45.

82. Chen H, Li C, Zemlicka J, Gentry BG, Bowlin TL, Coen DM. Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother. 2016;60(7):4176–82.

83. Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother. 2011;55(1):382–4.

84. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother. 2010;54(6):2371–8.

85. Chou S, Marousek G, Bowlin TL. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother. 2012;56(1):197–201.

86. Gentry BG, Drach JC. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob Agents Chemother. 2014;58(4):2329–33.

87. Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC. Oral activity of a methylene-cyclopropyl analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother. 2004;48(12):4745–53.

88. Bowlin TL, Brooks J, Zemlicka J. Preclinical pharmacokinetic, Toxicokinetic and toxicology results for cyclopropavir, a promising new agent for the treatment of beta- and gamma-herpesviruses. Antivir Res. 2009;82(2):A46–A7.
89. Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, et al. Phase Ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of filoviricidin (MBX-400, cyclopropavar) in healthy volunteers. Antimicrobial agents and chemotherapy. 2019;66(9).

90. Wu Z, Drach JC, Prichard MN, Yanachkova M, Yanachkov I, Bowlin TL, et al. L-valine ester of cyclopropavar: a new antiviral produg. Antivir Chem Chemother. 2009;20(1):37–46.

91. James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, et al. Alkoxylalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002;46(8):2381–6.

92. Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. Defective human cytomegalovirus (CMV) vaccine in CMV-Rupp R, et al. Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Science translational medicine. 2016;8(362):362ra145.

93. Adler SP, Lewis N, Conlon A, Christiansen MP, Al-Ibrahim M, Rupp R, et al. Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects. J Infect Dis. 2019;220(3):411–9.

94. Liu Y, Freed DC, Li L, Tang A, Li F, Murray EM, et al. A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection. J Virol. 2019;93(23).

95. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (New York). NY, 1992;257(5067):238–241.

96. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–44.

97. Feuchtiger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissing EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–7.

98. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.

99. Einsele H, Roosenek E, Ruler N, Sinzger C, Rieger S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–22.

100. Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, et al. Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after Haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017;216(8):945–56.

101. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121(18):3745–58.

102. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50(4):1130–5.

103. Mackinnon S, Thomson K, Verfuhrth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40(1):63–7.

104. Micklethwait K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(6):707–14.

105. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5D35pp65 gene-modified dendritic cells after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(10):3974–81.

106. Peggs KS, Verfuhrth S, Pitzez A, Khan N, Givier M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362(9393):1375–7.

107. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabo P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.

108. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31):3547–57 Provides additional support for the safety of adoptive immunotherapy using third-party donor T cells.

109. Withers B, Blyth E, Clancy LE, Yong A, Fraser C, Burgess J, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017;1(24):2193–205 Provides additional support for the safety of adoptive immunotherapy using third-party donor T cells.
118. Boeckh M, Corey L. Adoptive immunotherapy of viral infections: should infectious disease embrace cellular immunotherapy? J Infect Dis. 2017;216(8):926–8.

119. Ljungman P, Cordonnier C, Einsle H, Bender-Gotze C, Bosi A, Dekker A, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 1998;21(5):473–6.

120. Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30(6):554–61.

121. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109(10):777–82.

122. Reed EC, Bowden RA, Dandiker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109(10):783–8.

123. Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61(1):31–9.

124. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant [see comments]. J Infect Dis. 1991;164(3):483–7.

125. Bowden RA, Sayers M, Flournay N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314(16):1006–10.

126. Ruutu T, Ljungman P, Brinch L, Lennhoff S, Lonqvist B, Ringden O, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant. 1997;19(3):233–6.

127. Bass E, Powe N, Goodman S, Graziano S, Griffiths R, Kicker T, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1993;12:179–83.

128. Messori A, Rampazzo R, Scrocchi G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta analysis. Bone Marrow Transplant. 1994;13:163–8.

129. Raanani P, Gafer-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shipilberg O. Immunoglobulin prophylaxis in patients undergoing haematopoietic stem cell transplantation: systematic review and meta-analysis. Bone Marrow Transplantation. 2008;46(abstract Q267).

130. Sullivan KM, Kopecky KJ, Jocol J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):705–12.

131. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106(1):12–8.
147. Waldman WJ, Knight DA, Blinder L, Shen J, Lurain NS, Miller DM, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999;42(5–6):412–8.

148. Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999;68(6):814–25.

149. Zhang C, Chu M. Leflunomide: a promising drug with good anti-tumor potential. Biochem Biophys Res Commun. 2018;496(2):726–30.

150. Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother. 2004;48(11):4154–62.

151. Hutterer C, Hamilton S, Steingruber M, Zeittrager I, Bahsi H, Thuma N, et al. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors. Antivir Res. 2016;134:130–43.

152. Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, et al. Protein kinase inhibitors of the quinazoline class exert anticytomegaloviral activity in vitro and in vivo. Antivir Res. 2008;79(1):49–61.

153. Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.